Traditional Culture Encyclopedia - Traditional stories - Is there a disadvantage in biological immunotherapy for cancer?

Is there a disadvantage in biological immunotherapy for cancer?

The cost of biological immunotherapy for cancer is relatively high. In addition, because the biological immunotherapy of cancer is actually recurrent, it may not be completely controlled after treatment, which leaves some hidden dangers for the recurrence of cancer. Iveka, an immune anticancer drug, is an innovative immune macromolecular drug developed by Picard Immune Technology Platform, which belongs to a kind of therapeutic biological products and the third macromolecular immune biological product launched by Picard Immune Technology Platform to enter the clinical research and development stage. The price is cheaper than other products.